Targeting interleukin-2 to the bone Marrow stroma for therapy of acute myeloid Leukemia relapsing after allogeneic hematopoietic stem cell transplantation

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 547-556

  Schliemann, Christoph ^a   Gutbrodt, Katrin L ^b   Kerkhoff, Andrea ^a   Pohlen, Michele ^a   Wiebe, Stefanie ^a   Silling, Gerda ^a   Angenendt, Linus ^a   Kessler, Torsten ^a   Mesters, Rolf M ^a   Giovannoni, Leonardo ^c   Schäfers, Michael ^a   Altvater, Bianca ^a   Rossig, Claudia ^a   Grünewald, Inga ^d   Wardelmann, Eva ^d   Köhler, Gabriele ^d,e   Neri, Dario ^b   Stelljes, Matthias ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ETH ZURICH   (Switzerland)

^c Philogen SpA   (Italy)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e KLINIKUM FULDA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIINFECTIVE AGENT; BUSULFAN; CORTICOSTEROID; CREATININE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GLUCOCORTICOID; IDARUBICIN; INTERLEUKIN 2; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; PARACETAMOL; STEROID; TELEUKIN; THYMOCYTE ANTIBODY; TIOGUANINE; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; TENASCIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIMICROBIAL THERAPY; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW STROMA CELL; CANCER IMMUNOTHERAPY; CASE REPORT; CELL INFILTRATION; CHILL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE SYNDROME; DISSEMINATED MYELOSARCOMA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; EFFECTOR CELL; EXTRACELLULAR MATRIX; FATIGUE; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INTENSIVE CARE; KARNOFSKY PERFORMANCE STATUS; KARYOTYPE 46,XY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LUNG INFILTRATE; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PLEURA EFFUSION; PROTEIN EXPRESSION; RESPIRATORY DISTRESS; SARCOMA; SIDE EFFECT; STROMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT GAIN; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BONE MARROW; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RECURRENCE; TENASCIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84962236885     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0179     Document Type: Article

References (34)

1. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12:699-709.
2. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007;1776:175-92.
3. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5: 436-46.
4. Thorpe PE. Vascular targeting agents ascancer therapeutics. Clin Cancer Res 2004;10:415-27.
5. Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013; 5:201ra118.
6. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009;113:2265-74.
7. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009;113:2275-83.
8. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesisinthe bone marrow ofpatients with acute myeloid leukemia. Blood 2000;95:2637-44.
9. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012;17:583-90.
10. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009;11:R142.
11. Rosenow F, Berkemeier A, Krug U, Muller-Tidow C, Gerss J, Silling G, et al. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant 2013;48:1070-6.
12. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D. Threeclinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009;33:1718-22.
13. Bieker R, Padro T, Kramer J, Steins M, Kessler T, Retzlaff S, et al. Over-expression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 2003;63:7241-6.
14. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H, et al. Over-expression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302-10.
15. Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T, et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006; 91:1203-11.
16. Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood 2012;120:4706-11.
17. Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007;21:1310-2.
18. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24.
19. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells ingraft-versus-host disease. N Engl J Med 2011;365:2055-66.
20. Kennedy-Nasser A, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic HSCT mediates expansion of regulatory T cells without diminishing anti-viral and antileukemic activity. Clin Cancer Res 2014;20:2215-25.
21. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
22. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006;108:390-9.
23. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003;9:243-56.
24. Guichelaar T, Emmelot ME, Rozemuller H, Martini B, Groen RW, Storm G, et al. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res 2013;19:1467-75.
25. Guichelaar T, Mutis T. Bone marrow provides an environment that prevents suppression of therapeutic graft-vs.-tumor immunity by regulatory T cells. Oncoimmunology 2013;2:e24659.
26. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710.
27. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimericantigenreceptor-modifiedTcellsfor acutelymphoidleukemia. N Engl J Med 2013;368:1509-18.
28. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phaseIclinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010;46:2926-35.
29. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
30. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, et al. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 2008;14: 6515-24.
31. Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 2012;53:922-7.
32. Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco C, et al. Radioimmunotherapy with Tenarad, a I-labelledantibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2014;41:867-77.
33. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003;102: 4384-92.
34. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 2011;17:7732-42.